Hostname: page-component-78c5997874-fbnjt Total loading time: 0 Render date: 2024-11-10T22:49:36.571Z Has data issue: false hasContentIssue false
  • English
  • Français

APOE ε4 and the risk for Alzheimer disease and cognitive decline in African Americans and Yoruba

Published online by Cambridge University Press:  24 February 2014

Hugh C. Hendrie ,
Jill Murrell ,
Olusegun Baiyewu ,
Kathleen A. Lane ,
Christianna Purnell ,
Adesola Ogunniyi ,
Frederick W. Unverzagt ,
Kathleen Hall ,
Christopher M. Callahan  and
Andrew J. Saykin
...Show all authors
Hugh C. Hendrie*
Affiliation:
Indiana University Center for Aging Research, Indianapolis, Indiana, USA Regenstrief Institute, Inc., Indianapolis, Indiana, USA Department of Psychiatry, Indiana University School of Medicine, Indianapolis, Indiana, USA
Jill Murrell
Affiliation:
Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA
Olusegun Baiyewu
Affiliation:
Department of Psychiatry, College of Medicine, University of Ibadan, Ibadan, Nigeria
Kathleen A. Lane
Affiliation:
Department of Biostatistics, Indiana University School of Medicine, Indianapolis, Indiana, USA
Christianna Purnell
Affiliation:
Regenstrief Institute, Inc., Indianapolis, Indiana, USA
Adesola Ogunniyi
Affiliation:
Department of Medicine, College of Medicine, University of Ibadan, Ibadan, Nigeria
Frederick W. Unverzagt
Affiliation:
Department of Psychiatry, Indiana University School of Medicine, Indianapolis, Indiana, USA
Kathleen Hall
Affiliation:
Department of Psychiatry, Indiana University School of Medicine, Indianapolis, Indiana, USA
Christopher M. Callahan
Affiliation:
Indiana University Center for Aging Research, Indianapolis, Indiana, USA Regenstrief Institute, Inc., Indianapolis, Indiana, USA Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA
Andrew J. Saykin
Affiliation:
Department of Radiology and Imaging Services, Indiana University School of Medicine, Indianapolis, Indiana, USA
Oye Gureje
Affiliation:
Department of Psychiatry, College of Medicine, University of Ibadan, Ibadan, Nigeria
Ann Hake
Affiliation:
Department of Neurology, Indiana University School of Medicine, Indianapolis, Indiana, USA
Tatiana Foroud
Affiliation:
Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, Indiana, USA
Sujuan Gao
Affiliation:
Department of Biostatistics, Indiana University School of Medicine, Indianapolis, Indiana, USA
*
Correspondence should be addressed to: Hugh C. Hendrie, MB, ChB, DSc, Indiana University Center for Aging Research, 410 W 10th St., Suite 2000, Indianapolis, IN 46202, USA. Phone: (317) 423-5591; Fax: (317) 423-5695. Email: hhendri@iupui.edu.
Get access Rights & Permissions [Opens in a new window]

Abstract

Background:

There is little information on the association of the APOEe4 allele and AD risk in African populations. In previous analyses from the Indianapolis-Ibadan dementia project, we have reported that APOE ε4 increased the risk for Alzheimer's disease (AD) in African Americans but not in Yoruba. This study represents a replication of this earlier work using enriched cohorts and extending the analysis to include cognitive decline.

Methods:

In this longitudinal study of two community dwelling cohorts of elderly Yoruba and African Americans, APOE genotyping was conducted from blood samples taken on or before 2001 (1,871 African Americans & 2,200 Yoruba). Mean follow up time was 8.5 years for African Americans and 8.8 years for Yoruba. The effects of heterozygosity or homozygosity of ε4 and of the possession of e4 on time to incident AD and on cognitive decline were determined using Cox's proportional hazards regression and mixed effects models.

Results:

After adjusting for covariates, one or two copies of the APOE ε4 allele were significant risk factors for incident AD (p < 0.0001) and cognitive decline in the African-American population (p < 0001). In the Yoruba, only homozygosity for APOE ε4 was a significant risk factor for AD (p = 0.0002) but not for cognitive decline (p = 0.2346), however, possession of an e4 allele was significant for both incident AD (p = 0.0489) and cognitive decline (p = 0.0425).

Conclusions:

In this large longitudinal comparative study, APOE ε4 had a significant, but weaker, effect on incident AD and on cognitive decline in Yoruba than in African Americans. The reasons for these differences remain unclear.

Keywords

Alzheimer diseasecognitive impairmentAPOE ε4African AmericansYoruba
Type
Research Article
Information
International Psychogeriatrics , Volume 26 , Issue 6 , June 2014 , pp. 977 - 985
Copyright
Copyright © International Psychogeriatric Association 2014 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

American Psychiatric Association (1987). Diagnostic and Statistical Manual of Mental Disorders, 3rd edn, revised. Washington, DC: American Psychiatric Assocation.Google Scholar
American Pychiatric Association Press (1992). ICD-10. The International Statistical Classification of Diseases and Related Health Problems: 1 and 2.Google Scholar
Bell, J. T. et al. (2011). DNA methylation patterns associate with genetic and gene expression variation in HapMap cell lines. Genome Biology, 12, R10.Google Scholar
Chalise, P., Chicken, E. and McGee, D. (2011) Baseline age effect on parameter estimates in Cox models. Journal of Statistical Computation and Simulation, 82, 1767–1774.Google Scholar
Chen, C. H. et al. (2010). A comparative study to screen dementia and APOE genotypes in an ageing East African population. Neurobiol Aging, 31, 732–740.Google Scholar
Chuang, Y. F. et al. (2010). Association between APOE epsilon4 allele and vascular dementia: the Cache County study. Dementia and Geriatric Cognitive Disorders, 29, 248–253.CrossRefGoogle ScholarPubMed
Corbo, R. M. and Scacchi, R. (1999). Apolipoprotein E (APOE) allele distribution in the world. Is APOE*4 a ‘thrifty’ allele? Annals of Human Genetics, 63, 301–310.CrossRefGoogle ScholarPubMed
Deeg, M. et al. (2008). A comparison of cardiovascular disease risk factor biomarkers in African Americans and Yoruba Nigerians. Ethnicity & Disease, 18, 427–433.Google Scholar
Degner, J. F. et al. (2012). DNase I sensitivity QTLs are a jamor determinant of human expression variation. Nature, 482, 390–394.CrossRefGoogle Scholar
Evans, R. M. et al. (2000). Serum cholesterol, APOE genotype, and the risk of Alzheimer's disease: a population-based study of African Americans. Neurology, 54, 240–242.Google Scholar
Farrer, L. A. et al. (1997). Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA, 278, 1349–1356.CrossRefGoogle ScholarPubMed
Finch, C. E. and Sapolsky, R. M. (1999). The evolution of Alzheimer disease, the reproductive schedule, and APOE isoforms. Neurobiology of Aging, 20, 407–428.CrossRefGoogle ScholarPubMed
Finch, C. E. and Stanford, C. B. (2004). Meat-adaptive genes and the evolution of slower aging in humans. Quarterly Review of Biology, 63, 301–310.Google Scholar
Gureje, O. et al. (2006). APOE epsilon4 is not associated with Alzheimer's disease in elderly Nigerians. Annals of Human Genetics, 59, 182–185.Google Scholar
Hall, K. S., Gao, S., Emsley, C. L., Ogunniyi, A. O., Morgan, O. and Hendrie, H. C. (2000). Community screening interview for dementia (CSI ‘D’); performance in five disparate study sites. International Journal of Geriatric Psychiatry, 15, 521–531.3.0.CO;2-F>CrossRefGoogle ScholarPubMed
Hall, K. et al. (2006) Cholesterol, APOE genotype, and Alzheimer disease: an epidemiologic study of Nigerian Yoruba. Neurology, 66, 223–227.CrossRefGoogle ScholarPubMed
Hendrie, H. C. et al. (1988). The CAMDEX: a standardized instrument for the diagnosis of mental disorder in the elderly: a replication with a US sample. Journal of the American Geriatrics Society, 36, 402–408.CrossRefGoogle ScholarPubMed
Hendrie, H. C. et al. (2001). Incidence of dementia and Alzheimer disease in 2 communities: Yoruba residing in Ibadan, Nigeria, and African Americans residing in Indianapolis, Indiana. JAMA, 285, 739–747.CrossRefGoogle ScholarPubMed
Hendrie, H. et al. (2004). Alzheimer's disease, genes, and environment: the value of international studies. Canadian Journal of Psychiatry, 49, 92–99.Google Scholar
Hendrie, H. C. et al. (2006). The development of a semi-structured home interview (CHIF) to directly assess function in cognitively impaired elderly people in two cultures. International Psychogeriatrics, 18, 653–666.CrossRefGoogle ScholarPubMed
Hendrie, H. et al. (2013). Homocysteine levels and dementia risk in Yoruba and African Americans. International Psychogeriatrics, 25, 1859–1866.Google Scholar
Hixson, J. E. and Vernier, D. T. (1990). Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. Journal of Lipid Research, 31, 545–548.Google Scholar
Knopman, D. S., Mosley, T. H., Catellier, D. J. and Coker, L. H. (2009). Fourteen-year longitudinal study of vascular risk factors, APOE genotype, and cognition: the ARIC MRI Study. Alzheimers Dementia, 5, 207–214.CrossRefGoogle ScholarPubMed
Kuller, L. H. et al. (1998). Relationship between ApoE, MRI findings, and cognitive function in the Cardiovascular Health Study. Stroke, 29, 388–398.CrossRefGoogle ScholarPubMed
Leffondre, K., Touraine, C., Helmer, C. and Joly, P. (2013). Internal-censored time-to-event and competing risk with death: is the illness-death model more accurate than the Cox model? International Journal of Epidemiology, 42, 1177–1186.Google Scholar
Martin, G. M. (1999). APOE alleles and lipophylic pathogens. Neurobiol Aging, 20, 441–443.CrossRefGoogle ScholarPubMed
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D. and Stadlan, E. M. (1984). Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology, 34, 939–944.CrossRefGoogle ScholarPubMed
Morris, J. C. et al. (1989). The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer's disease. Neurology, 39, 1159–1165.Google Scholar
Murrell, J. R. et al. (2006). Association of apolipoprotein E genotype and Alzheimer disease in African Americans. Archives of Neurology, 63, 431–434.CrossRefGoogle ScholarPubMed
Ohara, T. et al. (2011). Apolipoprotein genotype for prediction of Alzheimer's disease in older Japanese: the Hisayama Study. Journal of the American Geriatrics Society, 59, 1074–1079.Google Scholar
Reitz, C. et al. (2013). Variants in the ATP-binding cassette transporter (ABCA7), apolipoprotein E 4,and the risk of late-onset Alzheimer disease in African Americans. JAMA, 309, 1483–1492.Google Scholar
Sahota, A. et al. (1997). Apolipoprotein E-associated risk for Alzheimer's disease in the African-American population is genotype dependent. Annals of Neurology, 42, 659–661.Google Scholar
Sawyer, K., Sachs-Ericsson, N., Preacher, K. J. and Blazer, D. G. (2009). Racial differences in the influence of the APOE epsilon 4 allele on cognitive decline in a sample of community-dwelling older adults. Gerontology, 55, 32–40.Google Scholar
Stewart, R., Russ, C., Richards, M., Brayne, C., Lovestone, S. and Mann, A. (2001). Apolipoprotein E genotype, vascular risk and early cognitive impairment in an African Caribbean population. Dementia and Geriatric Cognitive Disorders, 12, 251–256.CrossRefGoogle Scholar
Tennessen, J. A. et al. (2012). Evolution and functional impact of rare coding variation from deep sequencing of human exomes. Science, 337, 64–69.Google Scholar
Tishkoff, S. A. et al. (2009). The genetic risk structure and history of Africans and African Americans. Science, 324, 1035–1044.Google Scholar
Unverzagt, F. W. et al. (2011). Incidence and risk factors for cognitive impairment no dementia and mild cognitive impairment in African Americans. Alzheimer Disease and Associated Disorders, 25, 4–10.CrossRefGoogle ScholarPubMed